Clinical trials: Hospitalized COVID-19
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences
Covid19
Estradiol and Progesterone in Hospitalized COVID-19 Patients
The purpose of this study is to determine to what extent a short systemic steroid therapy with estradiol and progesterone, administered early to hospitalized and confirmed COVID-19 positive patients of both sexes in addition to…
- Trial name
- NCT04865029
- Testing
- Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tulane University
Coronavirus Infection
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable by the initiation of…
- Trial name
- NCT04355637
- Testing
- Inhaled budesonide
- Where
- 14 sites in Argentina, Spain
- Volunteers
- 120 people
- Sponsor
- Sara Varea
Covid19
Lactoferrin in Covid-19 Hospitalized Patients
TRIAL LAC is a randomized double-blind non profit multicenter study with a nutritional product: bovine lactoferrin - Mosiac 200 mg.
- Trial name
- LAC (NCT04847791)
- Testing
- Bovine lactoferrin
- Where
- 2 sites in Italy
- Volunteers
- 194 people
- Sponsor
- Paolo Manzoni
COVID-19
Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia
SARS-CoV-2 infection is responsible for hypoxemic pneumonia, which is sometimes serious and associated with excess mortality. To date, with the exception of dexamethasone, which has shown clinical efficacy by reducing the…
- Trial name
- DICOV (NCT05563168)
- Where
- 21 sites in France
- Sponsor
- Hospices Civils de Lyon
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after…
- Trial name
- NCT04953234
- Testing
- NovoTTF-100L
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure GmbH
Covid-19, ARDS
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including…
- Conditions
- Covid-19, ARDS, Pneumonia
- Trial name
- NCT04365764
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Covid19
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
The coronavirus disease 2019 (COVID-19) was classified as a pandemic by the World Health Organization (WHO) in March 2020. The SARS-COV-2 virus is easily transmissible and there is currently no approved treatment with effective…
- Trial name
- NCT04803370
- Testing
- Convalescent Plasma with antibody against SARS-CoV-2., Standard treatment for COVID-19
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Hospital Son Llatzer
Secondary Sclerosing Cholangitis, COVID-19
SSC-COVID in Patients After COVID-19
Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic
- Trial name
- NCT05233553
- Testing
- control of liver enzymes
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- University Hospital Tuebingen
COVID-19, Vaccine Effectiveness Against COVID-19
COVID-19 Effectiveness Study in the Philippines
This is a multi-site, observational, prospective test negative design case-control study which primarily aims to determine the protective effectiveness of 2 doses of an inactivated COVID-19 vaccine at least 14 days after the…
- Conditions
- COVID-19, Vaccine Effectiveness Against COVID-19, Hospitalized COVID-19
- Trial name
- NCT05518760
- Testing
- no intervention
- Where
- Philippines
- Volunteers
- 3,000 people
- Sponsor
- University of the Philippines
COVID-19
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease.
- Trial name
- PLASCOSSA (NCT04372979)
- Testing
- Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19
COVID-19 Algorithm Treatment at Home
The newly recognised disease COVID-19 is caused by the Severe-Acute-Respiratory-Syndrome Coronavirus 2 (SARS-CoV-2), which rapidly spread globally in late 2019, reaching pandemic proportions.
- Trial name
- COVER-HOME (NCT05413642)
- Testing
- Recommended treatment schedule, Usual care
- Sponsor
- Mario Negri Institute for Pharmacological Research
COVID-19
MP1032 Treatment in Patients With Moderate to Severe COVID-19
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04932941
- Testing
- MP1032
- Where
- 31 sites in United States, Bulgaria and 5 more
- Volunteers
- 132 people
- Sponsor
- MetrioPharm AG
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Covid19, COVID-19 Pneumonia
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
COVID-19 is respiratory disease caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), a novel coronavirus which has spread rapidly across the world with over 149.9 million laboratory confirmed cases and over 3.1…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Lower Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- COVASP (NCT04896866)
- Testing
- Antimicrobial stewardship prospective audit and feedback
- Where
- 3 sites in Canada
- Volunteers
- 833 people
- Sponsor
- University of Alberta
Pneumonia, Interstitial
Study Testing Convalescent Plasma vs Best Supportive Care
Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.
- Trial name
- NCT04333251
- Testing
- high-titer anti-Sars-CoV-2 plasma, oxygen therapy
- Sponsor
- Baylor Research Institute
COVID-19
Tetrandrine Tablets Used in Hospitalized Adults With COVID-19
The primary objective of this study is to evaluate the effectiveness of tetrandrine tablets in preventing the progression of COVID-19 from severe to critical.
- Trial name
- NCT05697029
- Testing
- Tetrandrine
- Where
- China
- Sponsor
- Peking University Third Hospital
SARS-CoV-2 Infection
Microvascular Injury and Distal Thrombosis in COVID-19
Investigators aimed to better understand the pathophysiology of SARS-CoV-2 pneumonia in non-critically ill hospitalized patients secondarily presenting with clinical deterioration and increase in oxygen requirement
- Trial name
- MIND (NCT04990505)
- Testing
- lung ventilation/perfusion scintigraphy
- Where
- Monaco
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Princesse Grace